| Name | Title | Contact Details |
|---|
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero`s existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Arcxis Biotechnologies Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.
Annovis Bio is developing a drug for Alzheimers Disease, Parkinsons Disease and other neurodegenerative diseases that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport.
Klox Technologies is a Canadian specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform. This non-invasive, pathology-specific topical treatment platform harnesses the power of light and photo activated oxygen-rich gel formulations to target various skin and soft tissue disorders. With franchises in dermatology, wound care, and oral health, Klox Technologies is well positioned to capitalize on significant market opportunities. We believe that our dedication to providing healthcare professionals with novel and effective treatment solutions will allow patients to experience positive results without some of the side effects associated with existing treatments. Klox Technologies’ senior management team has over 80 years of combined experience in the biotechnology, pharmaceutical, and medical devices industries. We continue to research, develop, and commercialize solutions based on our BioPhotonic technology platform for a growing and aging population that is seeking more effective and less invasive treatment options to improve their health and quality of life.